DYAI•DYAI•Japan Patent Office allowed claims for Dyadic’s proprietary Thermothelomyces heterothallica expression technology, bolstering the company’s IP portfolio in Japan. Dyadic engaged Intralink to pursue strategic collaborations and commercial opportunities, scheduling partner meetings in early July to expand its C1 and Dapibus™ recombinant protein platforms across life science and industrial sectors.
The Japan Patent Office has granted claims for Dyadic’s Thermothelomyces heterothallica recombinant protein expression technology, extending protection for its proprietary C1 and Dapibus™ microbial production platforms. This allowance reinforces Dyadic’s global intellectual property portfolio and secures its competitive position in one of the world’s most advanced biotechnology markets.
Dyadic engaged Intralink to support market expansion efforts in Japan and other key regions, generating targeted engagement opportunities with prospective biotech, pharmaceutical, food, nutrition, cosmetics and industrial partners. Company leadership is undertaking a business development visit in early July to meet with high-potential collaborators and customers, accelerating commercial discussions.
Japan’s leadership in regenerative medicine, biologics manufacturing and precision fermentation makes it a vital market for Dyadic’s recombinant protein solutions. The strengthened IP protection, combined with local business development support and planned engagements, positions Dyadic to capture rising demand for scalable protein production across multiple high-growth sectors.
